Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.SN Bioscience’s SNB-101 received FDA orphan drug designation
This development is based on pre-clinical findings of the drug in treating pancreatic cancer, a condition with a notably low five-year survival rate and limited treatment options. SNB-101
This development is based on pre-clinical findings of the drug in treating pancreatic cancer, a condition with a notably low five-year survival rate and limited treatment options. SNB-101
The facility, which will be operational this month, is designed to meet the increasing demand for life science products in the region. Spanning 13,000m2, the centre is twice
The investment, led by MSD Global Health Innovation Fund and IQ Capital, with contributions from Hoxton Ventures, Creator Fund, Beast Ventures, and Maki.vc, will expedite the progress of
The recommendation for granting Type II variation approval supports the use of cilta-cel for adult patients with RRMM who have received a minimum of one therapy earlier, including
Artiva had previously secured FDA clearance for an investigational new drug application for AlloNK plus rituximab for LN. This marked the first IND clearance for an allogeneic, off-the-shelf
Concurrently, the European Medicines Agency (EMA) granted accelerated assessment for the marketing authorization application (MAA) of the same drug. On receipt of approval, vorasidenib would become the sixth
The financing round was spearheaded by Broadview Ventures, with additional support from current investor SCVC and new participant MEIF Proof of Concept & Early Stage Fund. Mercia Ventures
This decision grants Everest the full ownership of intellectual property rights and worldwide rights for these products. The latest development is aimed at enhancing Everest’s flexibility in aligning
A humanised IgG2 monoclonal antibody, sibeprenlimab acts on the B-cell growth factor dubbed APRIL, a critical player in IgAN’s development and progression. By neutralising APRIL, the drug aims
This review could potentially lead to the approval of the first combination treatment offering an alternative to platinum-containing chemotherapy as the first-line treatment for locally advanced or metastatic